Sun Pharma Q2 profit rises 28% to ₹3,040 cr
The company’s revenue from operations increased 9% year-on-year to ₹13,291 crore for the second quarter.
The company’s revenue from operations increased 9% year-on-year to ₹13,291 crore for the second quarter.
Pharma billionaire sees 63% rise in net worth as acquisitions pay off.
Sun Pharma chairman leads the pack with a net worth of ₹2.32 lakh cr; Cyrus Poonawalla follows with ₹1.71 lakh crore.
The transaction marks the conclusion of a nearly 17-year effort to gain full control of the U.S.-listed generic drugmaker
As per the regulatory filing by the pharmaceutical major, through the acquisition, Sun Pharma aims to facilitate the consolidation of business in Israel.
Sun proposes to acquire outstanding shares of Taro’s at $43 apiece, up from $38 per share earlier
Dilip Shanghvi family and associate companies terminated shareholders' agreement with Suzlon, which was signed in February 2020.
The upfront payment of $8 per share of common stock in cash represents a premium of around 33% to Concert's 30-day volume weighted average price as of January 18, 2023.
The pharma company received a warning letter from the U.S. FDA for violations of manufacturing standards at the Halol facility in Gujarat.
Sun Pharma MD Dilip Shanghvi says in Q2, Sun Pharma recorded double-digit topline growth and strong margins, driven by market share gain in India, and sustained ramp-up of global specialty biz.